common
cold
preval
infect
human
adult
two
five
cold
year
schoolchildren
suffer
seven
cold
per
year
differ
type
viru
respons
human
upper
respiratori
tract
infect
common
rhinovirus
cold
follow
coronavirus
cold
influenza
virus
caus
cold
symptom
common
cold
result
viral
infect
upper
airway
incub
mani
organ
caus
respiratori
tract
infect
discuss
review
although
mani
respiratori
tract
infect
nonlifethreaten
associ
signific
level
morbid
oral
caviti
act
portal
entri
reservoir
mani
bacteri
viral
fungal
speci
microorgan
gain
access
interlink
airway
compos
mucos
epithelia
collect
compris
respiratori
tract
larg
mucos
surfac
area
act
reservoir
infecti
particl
inhal
good
evid
show
improv
oral
hygien
frequent
profession
healthcar
reduc
progress
occurr
respiratori
diseas
especi
amongst
highrisk
patient
group
formid
host
defenc
system
protect
lower
respiratori
tract
organ
must
first
negoti
nonspecif
mechan
upper
respiratori
tract
includ
mechan
wash
mechan
cough
respons
anatom
barrier
mucociliari
tree
addit
barrier
lower
respiratori
tract
includ
frequent
branch
pulmonari
tree
effect
aerodynam
filtrat
restrict
size
lm
alveolu
open
microorgan
reach
alveolu
must
resist
activ
phagocyt
immun
respons
cell
antimicrobi
defenc
factor
microorgan
overcom
subvert
innat
host
defenc
mucociliari
system
bronchoconstrict
cough
reflex
acquir
immun
mucos
immunoglobulin
infecti
process
begin
infect
may
acut
chronic
lower
respiratori
tract
infect
may
limit
bronchial
tree
bronchiti
lung
alveoli
pneumonia
involv
bronchopneumonia
virus
bacteria
caus
pharyng
tonsil
approxim
acut
sore
throat
viral
pharyng
often
occur
part
common
cold
influenza
also
caus
epsteinbarr
viru
herp
simplex
viru
certain
coxsacki
virus
herpangina
hand
foot
mouth
diseas
clinic
present
upper
respiratori
tract
infect
influenc
infect
viru
also
greatli
affect
age
physiolog
state
immunolog
experi
host
make
difficult
defin
precis
syndrom
wide
variat
sever
durat
type
symptom
period
day
flow
virusrich
fluid
nasopharynx
induc
infect
sneez
trigger
larg
number
viru
particl
expel
air
transmiss
aerosol
therefor
import
virus
also
spread
via
contamin
hand
thought
immun
respons
infect
main
factor
caus
symptom
particular
releas
complex
mixtur
proinflammatori
cytokin
mediat
bradykinin
believ
major
role
gener
local
symptom
eg
sore
throat
whilst
cytokin
respons
system
symptom
fever
detail
review
pathophysiolog
mechan
underli
common
cold
publish
recent
common
cold
typic
short
mild
ill
earli
symptom
includ
headach
sneez
chilli
sore
throat
later
symptom
compris
nasal
discharg
nasal
obstruct
cough
malais
sever
symptom
increas
rapidli
peak
day
mean
durat
symptom
day
diagnosi
made
clinic
specif
treatment
avail
common
cold
manag
focus
symptom
control
larg
literatur
prevent
manag
common
cold
mani
publish
studi
lack
scientif
rigor
area
review
recent
acut
bronchiti
inflammatori
condit
tracheobronchi
tree
character
cough
without
pneumonia
otherwis
healthi
patient
diseas
often
mild
complic
upper
respiratori
tract
viral
infect
degre
damag
respiratori
epithelium
vari
infecti
agent
secondari
bacteri
infect
streptococcu
pneumonia
haemophilu
influenza
see
may
also
play
role
pathogenesi
diseas
often
present
cough
initi
dri
pain
later
product
expector
greenish
sputum
treatment
larg
symptomat
diseas
mild
antibiot
frequent
prescrib
although
valu
uncertain
unless
ident
sensit
caus
agent
known
chronic
bronchiti
cough
excess
secret
mucu
present
tracheobronchi
tree
attribut
specif
diseas
tuberculosi
asthma
chronic
bronchiti
defin
cough
phlegm
least
month
everi
year
least
year
etiolog
factor
includ
infect
cigarett
smoke
inhal
toxic
dust
fume
whilst
infect
initi
diseas
signific
prolong
produc
acut
exacerb
caus
progress
lung
damag
may
lead
death
bacteria
eg
h
influenza
pneumonia
moraxella
catarrhali
virus
eg
influenza
coronavirus
commonli
associ
acut
bout
infect
treatment
complex
depend
sever
exacerb
caus
agent
pneumonia
lung
alveoli
becom
fill
edema
fluid
accompani
inflamm
lung
parenchyma
bacteria
may
enter
lung
inhal
aspir
oropharyng
fluid
latter
thought
common
rout
bacteri
pulmonari
infect
aspir
pneumonia
preval
communityacquir
pneumonia
well
hospitalacquir
pneumonia
pneumonia
may
classifi
lobar
consolid
lung
tissu
limit
one
lobe
segment
bronchopneumonia
consolid
scatter
throughout
lung
concentr
mainli
base
atyp
patchi
consolid
common
clinic
featur
pneumonia
includ
fever
rigor
malais
short
breath
cyanosi
product
cough
lung
consolid
case
pneumonia
acquir
commun
less
commonli
hospit
although
ventilatorassoci
pneumonia
import
problem
wide
rang
microorgan
may
implic
otherwis
healthi
individu
pneumonia
caus
pneumonia
virus
mycoplasma
pneumonia
patient
underli
diseas
may
develop
communityacquir
pneumonia
wider
rang
organ
includ
staphylococcu
aureu
h
influenza
klebsiella
pneumonia
pneumocysti
jiroveci
hospitalacquir
pneumonia
commonli
associ
aerob
facult
gramneg
bacilli
aureu
transmit
via
contamin
hand
healthcar
worker
instrument
equip
streptococcu
pneumonia
preval
pneumonia
also
design
pneumococci
lead
caus
morbid
mortal
worldwid
especi
young
old
immunocompromis
scotland
overal
incid
invas
pneumococc
diseas
case
per
per
infant
year
age
per
elderli
patient
year
age
recogn
serotyp
pneumonia
caus
case
invas
pneumococc
diseas
serotyp
pneumococci
preval
account
case
pneumococc
diseas
england
wale
also
recogn
import
relationship
exist
common
serotyp
pneumonia
emerg
resist
erythromycin
pneumonia
gramposit
coccu
normal
appear
pair
ahemolyt
georg
sternberg
loui
pasteur
independ
discov
import
organ
earli
experi
demonstr
genet
materi
consist
dna
pneumococc
pneumonia
occur
pneumococci
aspir
lung
clear
infect
activ
complement
protein
stimul
cytokin
product
attract
neutrophil
howev
pneumococci
adher
invad
differ
epitheli
endotheli
cell
use
cellspecif
mechan
intern
polysaccharid
capsul
signific
pathogenesi
infect
render
pneumococcu
resist
complementmedi
opsonophagocytosi
play
key
role
system
dissemin
variat
capsul
morpholog
associ
reduc
express
capsular
polysaccharid
addit
capsul
pneumococci
employ
signific
virul
factor
pneumolysin
neuraminidas
hyaluron
acid
autolysin
hydrogen
peroxid
cholinebind
protein
protect
antigen
pspa
symptom
pneumococc
pneumonia
begin
suddenli
sever
chill
usual
follow
high
fever
cough
short
breath
rapid
breath
chest
pain
seriou
complic
pneumococc
infect
mening
present
sever
persist
headach
stiff
neck
nausea
vomit
rapid
noninvas
diagnosi
pneumococc
pneumonia
carri
perform
sputum
gram
stain
although
depend
obtain
repres
sampl
patient
urinari
antigen
test
develop
altern
earli
noninvas
diagnost
method
limit
sensit
despit
high
specif
microbiolog
diagnosi
requir
cultur
organ
pneumococci
display
ahemolysi
blood
agar
within
h
incub
aerob
condit
optochin
sensit
distinguish
pneumonia
possibl
viridan
group
streptococci
serotyp
conduct
use
coagglutin
method
addit
method
multilocu
sequenc
type
conduct
enhanc
surveil
relationship
sequenc
type
serotyp
pneumococci
increas
preval
resist
penicillin
drug
among
pneumococci
consider
complic
empir
treatment
communityacquir
pneumonia
penicillin
resist
becom
widespread
global
resist
class
antibiot
tradit
use
altern
treatment
pneumococc
infect
also
increas
markedli
recent
year
area
usa
europ
east
asia
preval
macrolid
resist
high
recent
report
serotyp
one
common
serotyp
invas
pneumococci
resist
erythromycin
shown
highli
relat
clonal
type
combat
develop
resist
vaccin
becom
import
prevent
invas
pneumococc
diseas
polysaccharid
vaccin
avail
elicit
tcellindepend
respons
ineffect
children
year
age
licens
conjug
vaccin
contain
polysaccharid
serotyp
conjug
nondiphtheria
variant
carrier
protein
induc
high
antibodi
concentr
serotyp
initi
studi
assess
molecular
epidemiolog
pneumococcu
prior
vaccin
implement
immedi
afterward
studi
reveal
use
vaccin
reduc
burden
diseas
young
children
may
effect
prevent
diseas
adult
confer
herd
immun
unvaccin
popul
environment
nich
respiratori
tract
provid
favour
environ
h
influenza
colon
potenti
infect
six
capsular
antigen
type
h
influenza
capsul
strain
type
b
respons
human
infect
import
caus
pneumonia
mening
although
mani
nonencapsul
strain
also
caus
diseas
develop
countri
bangladesh
chile
gambia
death
h
influenza
pneumonia
greatli
outnumb
death
mening
diseas
burden
h
influenza
estim
seriou
ill
per
year
death
major
victim
less
year
age
follow
declin
matern
antibodi
children
month
age
vulner
epidemiolog
studi
document
h
influenza
nasopharyng
colon
rate
vari
human
higher
rate
children
adult
anticapsular
antibodi
good
opsonin
allow
bacteria
phagocytos
kill
antibodi
tcell
independ
produc
child
year
age
h
influenza
small
gramneg
rod
frequent
coccobacilliari
nonmotil
nonsporeform
facult
anaerob
six
antigen
distinct
capsular
type
recogn
af
also
nonencapsul
nontyp
organ
presenc
absenc
polysaccharid
capsul
determin
morpholog
coloni
pathogen
encapsul
bacteria
secret
capsular
polym
make
coloni
appear
umbil
h
influenza
requir
hematin
x
factor
nadp
v
factor
growth
differenti
speci
cultur
enrich
media
contain
factor
h
influenza
primarili
transmit
respiratori
droplet
infect
individu
carrier
adapt
well
limit
ecolog
nich
human
h
influenza
less
like
reli
environment
sens
strategi
use
fit
select
clonal
expans
popul
member
express
phenotyp
characterist
import
surviv
select
pressur
includ
host
immun
respons
nutrit
resourc
respiratori
mucosa
bloodstream
host
factor
bacteri
adher
cellular
penetr
hosttohost
transmiss
h
influenza
also
employ
virul
factor
immunoglobulin
proteas
pili
endotoxin
outer
membran
establish
infect
symptom
h
influenza
infect
includ
typic
associ
pneumonia
fever
cough
produc
sputum
short
breath
diagnosi
may
difficult
nonspecif
symptom
complic
includ
mening
sepsi
arthriti
diagnosi
h
influenza
laboratori
requir
cultur
chocol
agar
provid
x
v
factor
fastidi
organ
collect
specimen
blood
cultur
difficult
especi
young
children
highlight
need
noncultur
method
polymeras
chain
reaction
pcr
bexa
appropri
gene
detect
encapsul
h
influenza
type
f
bexa
conserv
capsular
gene
involv
export
capsular
materi
howev
mani
countri
vaccin
routin
nonencapsul
strain
predomin
caus
diseas
precis
method
character
isol
bacteri
pathogen
requir
understand
transmiss
track
spread
virul
antibioticresist
strain
monitor
impact
vaccin
bacteri
popul
multilocu
sequenc
type
nucleotid
sequencebas
approach
unambigu
character
isol
bacteria
offer
precis
accur
character
encapsul
nonencapsul
h
influenza
valu
continu
surveil
h
influenza
infect
entir
prevent
h
influenza
type
b
vaccin
highli
effect
avail
sinc
earli
major
develop
world
systemat
vaccin
virtual
elimin
h
influenza
type
b
industri
nation
diseas
result
capsular
type
vaccin
failur
prior
vaccin
avail
usa
per
children
less
year
age
becam
infect
h
influenza
type
b
decreas
per
figur
per
year
eightynin
countri
infant
vaccin
scheme
popul
vaccin
howev
vaccin
fulli
resolv
problem
h
influenza
infect
human
coverag
develop
countri
coverag
least
develop
countri
subsaharan
africa
polit
financi
issu
prevent
blanket
immun
cost
hib
vaccin
approxim
seven
time
higher
measl
polio
vaccin
thu
mening
remain
seriou
problem
children
year
age
area
hib
vaccin
use
similarli
strain
nontyp
h
influenza
vaccin
avail
continu
pose
problem
adult
essenti
antimicrobi
drug
use
care
avoid
signific
emerg
resist
preval
nineti
per
cent
legionellosi
associ
aerosolgener
devic
watercool
tower
shower
spa
pool
key
reservoir
fresh
water
except
legionella
pneumophila
found
pot
soil
remain
highli
underreport
organ
estim
case
legionella
infect
occur
year
usa
reason
underreport
l
pneumophila
part
usual
spectrum
diagnost
test
current
empir
therapi
negat
requir
identifi
etiolog
mani
case
fear
litig
would
prevent
bacterium
report
legionellosi
follow
trend
season
predilect
although
twofold
increas
case
associ
cool
tower
summer
month
legionellosi
diseas
socal
refer
first
record
outbreak
travel
group
member
american
legion
organ
mainli
associ
travel
detect
outbreak
difficult
rel
low
attack
rate
long
incub
period
dispers
affect
person
away
sourc
infect
contribut
underreport
diseas
dental
unit
water
line
dental
surgeri
equip
risk
develop
biofilm
environ
conduc
colon
legionella
speci
l
pneumophila
togeth
legionella
speci
detect
dental
unit
water
sever
studi
usa
austria
england
germani
exampl
one
american
studi
l
pneumophila
detect
water
sampl
taken
dental
unit
offic
distribut
fourstat
area
theoret
risk
infect
dental
treatment
indirect
evid
publish
serolog
studi
dental
staff
tend
support
conclus
howev
scientif
evid
date
water
dental
unit
ever
caus
diseas
l
pneumophila
gramneg
catalaseposit
bacterium
possess
polar
later
flagella
allow
rodshap
organ
motil
identifi
speci
compris
distinct
serogroup
within
legionella
genu
serogroup
l
pneumophila
confirm
case
l
pneumophila
caus
serogroup
legionella
capabl
intracellular
growth
host
cell
grow
optim
legionellosi
attribut
manmad
water
environ
increas
ambient
temperatur
upset
balanc
protozoa
bacteria
legionellosi
may
describ
diseas
result
human
intervent
nutrient
requir
growth
found
usual
water
environ
thu
legionella
surviv
intracellular
parasit
freeliv
protozoa
eg
ameba
ciliat
protozoa
slime
mold
microscop
observ
shown
legionella
multipli
intracellularli
protozoa
human
macrophag
experi
demonstr
cell
entri
phagocytosi
phagosom
fuse
lysosom
thu
bacteria
protect
bacteria
initi
multipl
becom
motil
within
cell
eventu
leav
lysi
remain
encyst
stationaryphas
gene
express
facilit
infect
new
host
cell
macrophag
infect
potenti
mip
gene
encod
surfac
protein
requir
effici
infect
host
cell
exact
mechan
known
mip
protein
exhibit
peptidylprolylci
tran
isomeras
activ
legionella
use
type
iv
secret
system
encod
factor
involv
assembl
activ
conjug
transfer
plasmid
dna
operon
may
deliv
virul
factor
requir
enter
host
cell
initi
infecti
process
three
key
syndrom
associ
legionella
diseas
sever
pneumonia
multisystem
failur
clinic
symptom
initi
diseas
eg
fever
nonproduct
cough
headach
myalgia
difficult
distinguish
pneumoniacaus
organ
pontiac
fever
selflimit
flulik
ill
subclin
seroconvers
asymptomat
legionella
identifi
growth
buffer
charcoal
yeastextract
agar
appropri
coloni
morpholog
requir
lcystein
isol
react
specif
antisera
known
legionella
speci
confirm
legionella
speci
within
legionellaca
distinguish
biochem
analysi
fatti
acid
profil
proteinband
pattern
serolog
nucleic
acid
analysi
gold
standard
diagnosi
legionellosi
remain
cultur
serolog
posit
patient
specif
sensit
legionella
isol
blood
lung
tissu
lung
biopsi
specimen
respiratori
secret
sputum
bronchial
alveolar
lavag
bronchial
aspir
stool
sampl
legionella
detect
respiratori
secret
direct
fluoresc
antibodi
sever
day
start
antimicrobi
therapi
urin
antigen
detect
permit
outbreak
recogn
allow
rapid
public
health
respons
captur
antibodi
use
major
assay
specif
l
pneumophila
serogroup
may
miss
case
legionellosi
impact
number
report
case
pcr
one
diagnost
test
potenti
detect
infect
caus
known
legionella
speci
detect
rrna
gene
mip
gene
empir
therapi
patient
hospit
communityacquir
pneumonia
includ
coverag
diseas
erythromycin
drug
choic
although
azithromycin
levofloxacin
licens
us
food
drug
administr
consid
prefer
tuberculosi
affect
human
least
year
despit
advanc
modern
medicin
still
caus
death
worldwid
infecti
diseas
accord
world
health
organ
report
global
tuberculosi
control
http
wwwwhoint
worldwid
epidem
threshold
declin
estim
million
new
case
tuberculosi
million
peopl
die
tuberculosi
includ
human
immunodefici
viru
hiv
new
case
million
asia
subsaharan
africa
estim
onethird
popul
infect
mycobacterium
tuberculosi
fortun
infect
actual
develop
tuberculosi
lifetim
howev
percentag
increas
highrisk
factor
involv
exampl
risk
person
infect
hiv
develop
tuberculosi
chang
lifetim
per
year
life
tuberculosi
caus
oblig
aerob
bacillu
tuberculosi
one
socal
tuberculosi
complex
six
speci
includ
mycobacterium
bovi
princip
caus
tuberculosi
cattl
mani
mammal
member
tuberculosi
complex
also
known
tubercl
bacilli
nonmotil
nonspor
noncapsul
straight
slightli
curv
rod
lm
length
width
size
grow
wide
rang
enrich
cultur
media
wide
use
lowensteinjensen
medium
human
tubercl
bacilli
produc
visibl
growth
lowensteinjensen
medium
week
although
primari
isol
clinic
sampl
growth
may
take
week
appear
optim
growth
temperatur
tubercl
bacilli
fail
grow
temperatur
less
tuberculosi
spread
human
aerosol
case
occup
tuberculosi
occur
healthcar
worker
follow
exposur
patient
known
activ
unsuspect
pulmonari
infect
tuberculosi
although
transmiss
tuberculosi
member
dental
profess
particular
problem
care
requir
patient
activ
diseas
treat
hospit
environ
isol
facil
exist
patient
becom
noninfecti
within
week
initi
effect
treatment
earli
cours
diseas
cell
tuberculosi
engulf
phagocyt
organ
surviv
intracellular
digest
even
multipli
within
destroy
phagocyt
howev
develop
cellmedi
immun
produc
macrophag
destroy
bacterium
cours
diseas
highli
depend
individu
host
respons
frequent
infect
lead
asymptomat
case
tuberculosi
radiograph
neg
skintest
posit
small
number
tuberculosi
may
remain
viabl
reactiv
later
date
infect
lead
symptomat
primari
tuberculosi
start
exud
lesion
lower
respiratori
tract
progress
product
lesion
cellmedi
immun
type
iv
hypersensit
develop
format
tubercl
heal
may
occur
point
lesion
may
extend
caseat
necrosi
may
heal
progress
massiv
destruct
lung
tissu
caviti
format
hematogen
spread
tuberculosi
lung
bodi
site
occur
otherwis
normal
patient
hivinfect
patient
spread
facilit
abil
tuberculosi
establish
intracellular
infect
tuberculosi
recur
later
life
tubercl
bacilli
remain
viabl
inact
bodi
previou
primari
infect
world
health
organ
estim
twothird
new
activ
case
tuberculosi
actual
result
reactiv
heal
primari
infect
clinic
featur
tuberculosi
includ
malais
headach
fever
persist
product
cough
blood
sputum
patient
also
suffer
weight
loss
night
sweat
diagnosi
tuberculosi
base
microscop
detect
acidfast
alcoholfast
bacilli
cultur
tuberculosi
sputum
togeth
skin
test
cultur
undertaken
agar
call
lowensteinjensen
medium
extrem
slow
week
howev
use
modern
bactec
radiometr
system
becton
dickinson
microbiolog
system
spark
md
usa
detect
time
reduc
day
molecular
biolog
method
appli
laboratori
diagnosi
dna
probe
identifi
tuberculosi
pure
cultur
within
hour
addit
use
pcrbase
diagnost
made
possibl
identifi
within
h
tuberculosi
clinic
specimen
technolog
becom
routin
futur
mantoux
test
consist
intraderm
inject
arm
purifi
protein
deriv
cultur
tuberculosi
posit
test
lesion
mm
diamet
site
inject
h
indic
either
activ
diseas
past
infect
neg
test
definit
rule
tuberculosi
falseneg
result
may
occur
patient
tuberculosi
usual
treat
three
four
drug
prevent
emerg
resist
strain
prolong
period
treatment
uk
regimen
compris
isoniazid
rifampicin
pyrazinamid
ethambutol
two
initi
month
follow
rifampicin
isoniazid
month
recommend
adult
respiratori
tuberculosi
howev
within
last
decad
multipl
drugresist
strain
tuberculosi
emerg
resist
isoniazid
rifampin
secondari
drug
less
effect
gener
toxic
includ
paraaminosalicyl
acid
streptomycin
amikacin
ciprofloxacin
clarithromycin
even
concern
emerg
strain
known
xdr
tb
resist
firstlin
agent
inject
agent
fluoroquinolon
strain
virtual
untreat
carri
mortal
worryingli
recent
center
diseas
control
world
health
organ
studi
isol
compris
examin
bacil
vaccin
live
avirul
bovin
strain
mycobacterium
use
almost
worldwid
usa
vaccin
tuberculosi
purifi
protein
derivativeneg
person
unfortun
protect
variabl
stronger
children
adult
signific
research
effort
underway
develop
new
effect
vaccin
rang
virus
caus
pneumonia
particularli
children
absenc
laboratori
cultur
data
difficult
differenti
clinic
viral
bacteri
pneumonia
presum
case
viral
pneumonia
specif
viral
agent
identifi
patient
influenza
season
epidem
diseas
occur
colder
month
temper
clime
occasion
follow
antigen
drift
viru
see
sever
worldwid
pandem
occur
histor
interv
centuri
three
pandem
spanish
influenza
pandem
claim
estim
million
live
whilst
asian
hong
kong
outbreak
result
million
death
influenza
virus
rna
virus
classifi
genu
orthomyxoviru
two
type
b
caus
seriou
infect
human
influenza
virus
two
major
surfac
glycoprotein
antigen
hemagglutinin
respons
cell
attach
enzym
activ
neuraminidas
assist
viru
matur
releas
two
surfac
antigen
undergo
gradual
progress
antigen
variat
result
spontan
mutat
minor
chang
hemagglutinin
antigen
drift
allow
virus
escap
host
immun
caus
outbreak
typic
mild
diseas
winter
month
pandem
involv
emerg
new
influenza
subtyp
human
popul
caus
major
genet
reassort
rna
segment
code
viral
surfac
hemagglutinin
antigen
shift
creat
new
viru
human
popul
littl
protect
recent
evid
suggest
transmiss
influenza
occur
short
distanc
rather
long
distanc
predominantli
droplet
contact
rout
rather
aerosol
viral
particl
attach
sialic
acid
receptor
superfici
epitheli
cell
upper
lower
respiratori
tract
infect
kill
cytokin
releas
host
cell
caus
chill
malais
fever
muscular
ach
influenza
rare
caus
primari
pneumonia
damag
lung
usual
caus
secondari
bacteri
infect
pneumonia
aureu
h
influenza
howev
human
diseas
caus
see
primari
viral
pneumonia
multiorgan
failur
common
fever
cough
malais
myalgia
frequent
describ
symptom
influenza
difficult
differenti
viral
respiratori
infect
sever
studi
shown
import
fever
nonproduct
cough
distinguish
influenza
particularli
infect
known
present
commun
test
undertaken
earli
suspect
outbreak
confirm
influenza
circul
commun
test
also
undertaken
whenev
necessari
confirm
diagnosi
case
atyp
howev
need
carri
patient
present
typic
clinic
pictur
influenza
outbreak
viral
cultur
nasopharyng
specimen
sensit
specif
test
result
take
day
longer
limit
valu
clinic
rapid
test
influenza
avail
http
wwwcdcgovfluprofessionalsdiagnosislab
procedureshtm
help
individu
patient
result
contribut
diagnost
treatment
decis
hydrat
import
replac
larg
fluid
loss
associ
fever
antipyret
ibuprofen
reduc
fever
associ
symptom
evid
use
affect
durat
ill
prescrib
within
h
onset
symptom
uncompl
case
cours
neuraminidas
inhibitor
oseltamivir
zanamivir
reduc
durat
ill
day
drug
could
use
prophylact
agent
event
futur
pandem
vaccin
avail
need
review
annual
relat
genet
chang
occur
virus
circul
previou
year
vaccin
provid
protect
vaccine
valuabl
protect
highrisk
individu
especi
elderli
chronic
cardiopulmonari
diseas
healthcar
worker
recent
time
strain
influenza
develop
epizoot
domest
poultri
associ
human
infect
observ
first
hong
kong
subsequ
case
influenza
across
southeast
asia
russia
europ
africa
india
middl
east
total
number
human
case
date
low
current
strain
effici
transmit
human
human
octob
world
health
organ
confirm
case
countri
indonesia
vietnam
case
patient
die
case
fatal
rate
thu
human
diseas
caus
follow
aggress
cours
primari
viral
pneumonia
multiorgan
failur
common
furthermor
case
date
previous
healthi
children
adult
therefor
concern
major
mortal
global
genet
reassort
strain
emerg
readili
transmit
human
result
pandem
combin
vaccin
antivir
drug
oseltamivir
zanamir
util
attempt
reduc
impact
pandem
case
number
death
still
expect
extrem
high
massiv
social
societ
impact
novemb
outbreak
sever
respiratori
diseas
recogn
etiolog
report
guandong
provinc
china
agent
spread
wide
across
east
southeast
asia
part
world
notabl
toronto
canada
time
outbreak
control
juli
case
identifi
countri
august
case
sever
acut
respiratori
syndrom
death
report
worldwid
diseas
name
sever
acut
respiratori
syndrom
sar
symptom
includ
high
fever
cough
short
breath
difficulti
breath
chest
radiograph
consist
pneumonia
close
contact
infect
person
pose
greatest
transmiss
risk
mani
famili
member
healthcar
worker
becam
infect
caus
agent
known
new
coronaviru
name
sarsassoci
coronaviru
detect
pcr
serolog
specif
treatment
infect
patient
sever
symptom
requir
mechan
ventil
intens
care
unit
mortal
rate
may
high
elderli
number
fungi
affect
lower
respiratori
tract
lung
colon
allergi
direct
infect
microorgan
acquir
inhal
pathogen
fungal
spore
yeast
cell
case
asymptomat
undiagnos
may
involv
seriou
manifest
infecti
fungal
respiratori
diseas
divid
occur
gener
healthi
individu
occur
opportunist
immunosuppress
patient
healthi
individu
fungi
caus
respiratori
diseas
includ
organ
histoplasma
capsulatum
coccidioid
immiti
blastomyc
dermatitidi
pathogen
certain
geograph
region
infecti
fungal
respiratori
diseas
remain
import
caus
morbid
mortal
immunocompromis
individu
especi
receiv
immunosuppress
therapi
undergo
bone
marrow
transplant
solidorgan
transplant
hiv
infect
fungi
affect
immunosuppress
individu
frequent
speci
aspergillu
candida
well
cryptococcu
neoforman
p
jiroveci
rarer
fungi
fusarium
spp
zygomycet
pseudallescheria
boydii
penicillium
marneffii
newli
recogn
caus
agent
pulmonari
fungal
infect
pythium
insidiosum
absidia
corymbifera
phialemonium
obovatum
enterocytozoon
bieneu
hormographiella
aspergillata
irpex
lacteu
key
fungi
relat
respiratori
infect
discuss
aspergillu
spp
affect
immunocompromis
patient
leukemia
undergo
chemotherapi
treatment
steroid
transplant
patient
cystic
fibrosi
hiv
acquir
immunodefici
syndrom
aid
chronic
obstruct
pulmonari
diseas
chronic
granulomat
diseas
sever
asthma
fungal
sensit
mani
other
aspergillu
fumigatu
pathogen
speci
respons
case
invas
aspergillosi
three
main
clinic
syndrom
caus
fumigatu
greatest
predilect
speci
respiratori
tract
allerg
bronchopulmonari
aspergillosi
hypersensit
reaction
colon
airway
sinus
lung
aspergillu
spp
predominantli
affect
patient
asthma
cystic
fibrosi
bronchiectasi
clinic
syndrom
allerg
bronchopulmonari
aspergillosi
affect
approxim
asthma
cystic
fibrosi
aspergilloma
infect
preexist
pulmonari
caviti
mycetoma
fungal
ball
aspergillu
speci
variabl
preval
depend
amount
cavit
lung
diseas
affect
popul
question
invas
aspergillosi
dissemin
infect
affect
immunocompromis
individu
often
start
lung
may
involv
organ
tissu
hematogen
spread
invas
aspergillosi
extrem
rare
amongst
immunocompet
patient
howev
preval
rise
result
increas
number
patient
undergo
intens
chemotherapi
treat
neoplasm
receiv
organ
transplant
aspergillu
opportunist
filamentform
mold
genu
compris
spp
fumigatu
respons
major
human
aspergillu
infect
aspergillu
spp
univers
distribut
found
soil
organ
matter
four
aspergillu
spp
caus
remain
case
aspergillosi
name
aspergillu
terreu
aspergillu
flavu
aspergillu
niger
aspergillu
nidulan
terreu
associ
high
mortal
flavu
may
caus
sinus
commonli
niger
frequent
colon
speci
commonli
associ
extern
otiti
nidulan
particularli
associ
infect
chronic
granulomat
diseas
fumigatu
ubiquit
saprophyt
fungu
worldwid
distribut
result
part
product
small
spore
call
conidia
averag
size
lm
easili
dispers
air
remain
atmospher
prolong
period
time
depend
upon
extern
environ
temperatur
humid
season
variat
spore
fumigatu
hydrophob
proteincoat
layer
may
enabl
withstand
host
defenc
harsh
environ
addit
small
size
enabl
penetr
deep
lung
particularli
fumigatu
aspergillu
spp
also
form
hypha
septat
hyalin
one
key
virul
factor
aspergillu
requir
tissu
invas
fumigatu
grow
rapidli
extrem
thermotoler
bind
laminin
fibrinogen
effici
speci
aspergillu
make
awel
adapt
pathogen
morpholog
colour
conidiophor
vari
speci
allerg
bronchopulmonari
aspergillosi
frequent
present
wheez
pulmonari
infiltr
fever
cough
may
sever
result
expector
larg
mucou
plug
hemoptysi
may
coupl
gener
malais
sever
headach
aspergilloma
may
present
hemoptysi
lifethreaten
cough
fever
less
frequent
condit
may
asymptomat
detect
radiograph
chang
patient
preexist
cavit
lung
diseas
invas
aspergillosi
present
cough
combin
fever
short
breath
pleurit
chest
pain
pneumon
consolid
may
develop
rapidli
worsen
clinic
condit
sever
hypoxia
includ
hemoptysi
fungu
may
spread
blood
affect
kidney
brain
heart
spleen
liver
thyroid
gastrointestin
tract
eye
diagnosi
pulmonari
aspergillosi
difficult
requir
high
index
suspicion
histopatholog
lung
biopsi
remain
presenc
acut
dichotom
branch
septat
filament
form
invad
tissu
combin
pure
cultur
diagnost
chest
radiograph
featur
also
import
earli
stage
diseas
sign
includ
bronchopneumonia
consolid
segment
pneumonia
multipl
nodul
mass
cavitari
lesion
pleural
effus
comput
tomographi
scan
chest
reveal
multipl
nodul
characterist
halo
sign
cultur
bronchoalveloar
lavag
often
provid
use
indic
infect
adjunct
diagnost
test
recent
advanc
seen
use
galactomannan
detect
enzymelink
immunosorb
assay
galactomannan
cell
wall
polysaccharid
detect
blood
level
low
ng
ml
prior
develop
clinic
sign
howev
although
provid
high
neg
predictor
infect
limit
poor
posit
predict
valu
result
crossreact
speci
foodstuff
betadglucan
anoth
recent
antigen
detect
test
appear
promis
addit
diagnost
arsen
prospect
clinic
trial
necessari
evalu
technolog
pcr
test
current
develop
may
offer
high
specif
sensit
howev
distinguish
infect
colon
optim
specimen
collect
problemat
oral
longterm
highdos
steroid
mainstay
manag
allerg
bronchopulmonari
aspergillosi
coupl
treatment
itraconazol
aspergilloma
may
treat
surgic
associ
high
morbid
mortal
aspergilloma
percutan
administr
amphotericin
b
may
perform
studi
show
appar
benefit
convers
itraconazol
show
limit
success
high
tissu
penetr
term
invas
aspergillosi
ia
amphotericin
b
firstlin
therapi
aspergillosi
mani
year
associ
seriou
side
effect
nephrotox
howev
liposom
formul
introduc
fewer
side
effect
voriconazol
broadspectrum
triazol
recent
approv
treatment
ia
favour
outcom
amphotericin
b
fewer
side
effect
azol
includ
posaconazol
may
use
salvag
therapi
convent
antifung
fail
echinocandin
caspofungin
cell
wall
inhibitor
introduc
use
salvag
therapi
although
limit
clinic
studi
data
current
avail
potenti
combin
therapi
echinocandin
liposom
amphotericin
b
triazol
prophylaxi
highrisk
patient
group
preferenti
itraconazol
use
rel
effect
addit
report
immunotherapi
manag
patient
invas
aspergillosi
includ
colonystimul
factor
granulocyt
colonystimul
factor
granulocytemacrophag
colonystimul
factor
interferonc
recent
guidelin
treatment
aspergillosi
valuabl
resourc
manag
infect
speci
cryptococcu
describ
date
c
neoforman
pathogen
ubiquit
encapsul
roundtoov
yeastlik
fungu
measur
lm
initi
inhal
prior
caus
diseas
coccoccosi
affect
immunocompromis
individu
aid
immun
defici
cancer
steroid
use
diabet
possess
characterist
polysaccharid
capsul
variabl
thick
lm
surround
yeast
within
environ
capsul
thinner
yeast
smaller
thicker
capsul
tend
found
infect
tissu
polysaccharid
capsul
phenoloxidas
enzym
abil
grow
major
virul
factor
respiratori
manifest
diseas
acut
chronic
acut
form
diseas
rare
occur
patient
aid
present
sever
acut
respiratori
distress
chronic
pulmonari
form
associ
product
nodul
mass
usual
upper
lobe
caviti
segment
pneumonia
pleural
effus
lymphadenopathi
histolog
infect
appear
inflamm
gelatin
appear
compos
yeast
cell
becom
granulomat
diagnos
made
directli
visual
yeast
cell
biopsi
sampl
isol
indirect
diagnosi
made
detect
cryptococc
polysaccharid
antigen
use
commerci
avail
latex
agglutin
assay
p
jiroveci
formerli
pneumocysti
carinii
atyp
fungu
commonli
invad
respiratori
tract
usual
caus
asymptomat
infect
data
measur
specif
antibodi
level
p
jiroveci
suggest
children
colon
age
year
case
p
jiroveci
pneumonia
occur
otherwis
healthi
children
far
import
express
diseas
immunocompromis
especi
patient
aid
diagnost
method
p
jiroveci
includ
demonstr
microb
sputum
lungbiopsi
tissu
use
indirect
immunofluoresc
stain
monoclon
antibodi
treatment
involv
trimethoprimsulfamethoxazol
pentamidin
articl
review
respiratori
tract
infect
pneumonia
context
current
knowledg
bacteria
virus
fungi
respons
diseas
number
respiratori
tract
infect
includ
legionellosi
tuberculosi
potenti
transmit
dental
treatment
aspir
pneumonia
associ
member
oral
flora
common
among
hospit
debilit
patient
tuberculosi
global
concern
antibiot
resist
particularli
among
strain
known
xdr
tb
virtual
imposs
treat
chemotherapeut
agent
influenza
viru
caus
widespread
concern
potenti
pandem
strain
develop
transmit
readili
human
posit
note
improv
understand
genet
epidemiolog
two
import
bacteri
pathogen
pneumonia
h
influenza
result
signific
advanc
prevent
improv
vaccin
avail
effect
respiratori
tract
infect
continu
preval
human
popul
provid
ongo
challeng
modern
medicin
